Clinical Research Directory
Browse clinical research sites, groups, and studies.
Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored. Meanwhile, the dynamic molecular monitoring of neoadjuvant therapy in MIBC patients and the treatment guidance based on the MHC tumor immune microenvironment were also explored to select the treatment plan based on relevant biomarkers for subsequent immunotherapy in MIBC patients.
Official title: An Exploratory Study on the Remodeling of MHC-related Tumor Immune Microenvironment in Patients With Muscle-invasive Bladder Cancer After Neoadjuvant Therapy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2026-02-01
Completion Date
2027-05-01
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
Immunotherapy plus chemotherapy
The neoadjuvant therapy regimen for muscle-invasive bladder cancer is the GC regimen. This study does not alter the patients' neoadjuvant therapy regimen but adds toripalimab to the selected neoadjuvant treatment. After MDT discussion, eligible patients will receive GC combined with immunotherapy therapy.